Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine k...
Main Authors: | Bérengère Gobin, Gatien Moriceau, Benjamin Ory, Céline Charrier, Régis Brion, Frederic Blanchard, Françoise Redini, Dominique Heymann |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3944320?pdf=render |
Similar Items
-
Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil
by: Marcos Lima
Published: (2005-09-01) -
Imatinib mesylate-induced palmoplantar keratoderma
by: Niharika Jha, et al.
Published: (2021-01-01) -
Periorbital edema secondary to imatinib mesylate
by: Collin M McClelland, et al.
Published: (2010-05-01) -
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01) -
Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)